E-LIB Suche - Ergebnisse für: Boni, V. - Sprache DE

OpenAccess-Volltexte X

Personensuche X

Sortierung: Relevanz

Sortierung: Jahr

1

Phase Ia/b Study of Giredestrant ± Palbociclib and ± Lutein..:

Jhaveri, KL ; Bellet, M ; Turner, NC...
730005. , 2024

Link: https://repository.icr.a..

2

First-Line Ipatasertib, Atezolizumab, and Taxane Triplet fo..:

Schmid, P ; Turner, NC ; Barrios, CH...
731585. , 2024

Link: https://repository.icr.a..

3

A phase I trial of LXS196, a protein kinase C (PKC) inhibit..:

Piperno-Neumann, S ; Carlino, M. S ; Boni, V...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006169/. , 2023

Link: http://www.ncbi.nlm.nih...

4

Safety, Efficacy, and Biomarker Analyses of Dostarlimab in ..:

Oaknin, A ; Pothuri, B ; Gilbert, L...
727516. , 2023

Link: https://repository.icr.a..

5

Antitumor activity of lurbinectedin in combination with ora..:

Awada, A.H ; Boni, V ; Moreno, V...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808480/. , 2022

Link: http://www.ncbi.nlm.nih...

6

Lurbinectedin, a selective inhibitor of oncogenic transcrip..:

Boni, V ; Pistilli, B ; Braña, I...
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.esmoop.2022.100571. , 2022

Link: https://serval.unil.ch/n..

7

Lurbinectedin, a selective inhibitor of oncogenic transcrip..:

Boni, V ; Pistilli, B ; Braña, I...
http://hdl.handle.net/10668/22220. , 2022

Link: http://hdl.handle.net/10..

8

Efficacy and safety of larotrectinib in TRK fusion-positive..:

Doz, F ; van Tilburg, CM ; Geoerger, B...
issn:1522-8517. , 2022

Link: http://hdl.handle.net/11..

9

Lurbinectedin, a selective inhibitor of oncogenic transcrip..:

Boni, V ; Pistilli, B ; Braña, I...
http://hdl.handle.net/10668/22220. , 2022

Link: http://hdl.handle.net/10..

10

Lurbinectedin, a selective inhibitor of oncogenic transcrip..:

Boni, V ; Pistilli, B ; Braña, I...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588879/. , 2022

Link: http://www.ncbi.nlm.nih...

11

Effect of lurbinectedin on the QTc interval in patients wit..:

Fudio, S ; Tabernero, J ; Subbiah, V...
http://zaguan.unizar.es/record/97222. , 2021

Link: http://zaguan.unizar.es/..

12

RARE-07. EFFICACY AND SAFETY OF LAROTRECTINIB IN PEDIATRIC ..:

Perreault, S ; Doz, F ; Geoerger, B...
issn:1522-8517. , 2021

Link: http://hdl.handle.net/11..

13

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HR..:

Ho, AL ; Brana, I ; Haddad, R...
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, pp. JCO2002903 - ?. , 2021

Link: https://repository.icr.a..

14

CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advance..:

Naing, A ; Thistlethwaite, F ; De Vries, EGE...
https://discovery.ucl.ac.uk/id/eprint/10133504/1/e002447.full.pdf. , 2021

Link: https://discovery.ucl.ac..

15

Efficacy and safety of larotrectinib in TRK fusion-positive..:

Doz, F ; van Tilburg, CM ; Geoerger, B...
Neuro-Oncology. , 2021

Link: https://repository.icr.a..

1-15